Conference Reports for NATAP

20th Conference on Retroviruses and Opportunistic Infections Atlanta, GA March 3 - 6, 2013 Back

SECOND-LINE: Ritonavir-Boosted-Lopinavir with 2-3N(t)RTI or Raltegravir in HIV-Positive Subjects Virologically Failing First-Line NNRTI/2N(t)RTI antiretroviral therapy       Reported by Jules Levin CROI 2013   Allison Humphries and Mark Boyd on behalf of the SECOND-LINE study team Kirby Institute, University of New South Wales, Sydney, Australia